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Sirtuins are NAD+-dependent histone deacetylases regulating important metabolic pathways in prokaryotes and
eukaryotes and are involved in many biological processes such as cell survival, senescence, proliferation, apoptosis,
DNA repair, cell metabolism, and caloric restriction. The seven members of this family of enzymes are considered
potential targets for the treatment of human pathologies including neurodegenerative diseases, cardiovascular
diseases, and cancer. Furthermore, recent interest focusing on sirtuin modulators as epigenetic players in the
regulation of fundamental biological pathways has prompted increased efforts to discover new small molecules
able to modify sirtuin activity. Here, we review the role, mechanism of action, and biological function of the
seven sirtuins, as well as their inhibitors and activators.
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The mammalian sirtuin (SIRT) family, evolutionally
conserved proteins belonging to class III histone dea-
cetylases (HDACs), comprises seven members. SIRTs
share a NAD+-binding catalytic domain and may act
specifically on different substrates depending on the
biological processes in which they are involved (Table 1).
SIRTs differ in sequence and length in both their N- and
C-terminal domains, partially explaining their differ-
ent localization and functions. SIRTs can catalyze both
deacetylation and ADP-ribosylation [1]. Their best-
characterized activity is NAD+-dependent lysine dea-
cetylation, but recent studies demonstrated that some
SIRTs also remove other acyl groups such as succinyl,
malonyl, glutaryl, and long-chain fatty acyl groups [2, 3]
(Table 1). The last decade has seen growing interest in
their association with and involvement in different
pathologies, such as (but not restricted to) cancer and
neurodegenerative diseases. Increasing evidences sup-
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diseases and of SIRT activators (SIRTa) for age-related
disorders have led to the identification of many SIRT
modulators over recent years, mainly through chemical
library screening and catalytic mechanism-based design
approaches, often combined with structure-activity re-
lationship (SAR) investigations. Here, we provide a
summary of the most important SIRT activities and
SIRT modulators, their latest analogs, and novel che-
motypes (Tables 2 and 3).Sirtuins in physiology and pathology
SIRT1 was the first SIRT family member to be discov-
ered and is still the most studied. Its involvement in
many neuronal processes [4, 5] prompted further inves-
tigations into its role in neurological disorders such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), and
Huntington’s disease (HD) [6–8]. SIRT1 exerts a neuro-
protective action and is involved in survival, neuropath-
ology, and the expression of brain-derived neurotrophic
factor. In a mouse model of HD, SIRT1 knockout
results in exacerbation of the pathology, while its re-
expression displays neuroprotective effects [9]. A correl-
ation between nicotinamide phosphoribosyltransferase
(NAMPT) and SIRT1 was recently shown. NAMPT is
a therapeutic target against ischemic stroke, acting inis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Sirtuin location, activity, and effects on pathologies
Sirtuin Localization Enzymatic activity Histone
deacetylation target
Non-histone deacetylation
target
Pathology
SIRT1 Nuclear/
cytoplasmatic
Deacetylase H3K9ac Hif-1α, Hif-2α Neurodegenerative diseases.
Cancer: acute myeloid leukemia,
colon, prostate, ovarian, glioma,
breast, melanoma,
lung adenocarcinoma.
H1K26ac MYC
H4K16ac
SIRT2 Nuclear/
cytoplasmatic
Deacetylase H3K56ac Tubulin Neurodegenerative diseases.
Cancer: brain tissue, glioma.
H4K16ac Foxo3a
EIF5A
P53, G6PD, MYC
SIRT3 Mitochondrial Deacetylase H3K56ac SOD2, PDMC1a, IDH2,
GOT2, FoxO3a
Neurodegenerative diseases.
Cancer: B cell chronic lymphocytic
leukemia, mantle cell lymphoma,
chronic lymphocytic
leukemia, breast, gastric.
H4K14 ac
SIRT4 Mitochondrial ADP-ribosyltransferase Unknown GDH, PDH Cancer: breast, colorectal.
SIRT5 Mitochondrial Malonyl, succinyl,
glutaryl deacetylase
Unknown CPS1 Cancer: pancreatic, breast, non-small
cell lung carcinoma.
SIRT6 Nuclear Deacetylase, ADP-ribosyltransferase,
long-chain fatty acyl deacylase
H3K9ac Unknown Cancer: breast, colon.
H3K56ac
SIRT7 Nuclear Deacetylase H3K18ac Hif-1α, Hif-2α Cancer: liver, testis, spleen, thyroid,
breast.
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cetylation of NAMPT at K53 increased its activity and
secretion [10]. The first observations linking SIRT1 to
tumorigenesis came from two studies showing p53 dea-
cetylation and inhibition [11, 12], promoting cancer
cell death. In tumorigenesis, SIRT1 seems to play a
contradictory role, acting as both a tumor promoter
and tumor suppressor (by inhibiting oncogenes and
oncoproteins, similar to survivin) [13, 14]. SIRT1 regu-
lates many tumor suppressors and DNA repair genes
[15–18]. SIRT1 upregulation is described in many hu-
man malignancies [19]. Although its role in cancer re-
mains contradictory [20], recent studies showed that
patients expressing high levels of SIRT1 had a higher
chance of being resistant to chemotherapy than pa-
tients with low SIRT1 expression [21, 22]. One report
proposed a role for SIRT1 in melanoma and suggested
the use of inhibitors (tenovins, EX-527, and sirtinol),
either alone or in combination. These inhibitors act on
a variety of SIRTs, strengthening the idea that the con-
comitant inhibition of several SIRTs may contribute to
a reduction in malignant growth [23]. SIRT2, the sec-
ond member of the SIRT family, seems to exert a neu-
rodegenerative action in neurological disease [24].
Indeed, pharmacological or genetic inhibition of SIRT2
blocks of αSyn-mediated toxicity [25]. SIRT2 is in-
volved in apoptosis control through p53 process regu-
lation. Several studies confirm the role of SIRT2 in the
control of cell cycle progression at many levels. It wasdemonstrated that it is a checkpoint for metaphase/
anaphase processes and G2/M transition [26, 27]. Re-
cent studies indicated that SIRT2 might also act as a
tumor promoter or tumor suppressor in tumorigenesis,
likely displaying a regulatory function [28, 29]. More-
over studies about SIRT2 have shown its involvement
in metabolism processes, like adipogenesis [30]. SIRT2
is capable to deacetylate the Glucokinase (GCK), an es-
sential enzyme for maintaining homeostasis of glucose
regulated by the binding of the glucokinase regulatory
protein (GKRP). Acetylated GKRP is connected to dia-
betes mellitus [31]. Of the three mitochondrial SIRTs
(SIRT3, 4, and 5), some evidence correlates SIRT3 with
neurodegenerative disease. SIRT3 protects neurons in
the cochlea against oxidative damage during calorie re-
striction [32] and in response to stress-regulating mito-
chondrial antioxidant manganese superoxide dismutase
(MnSOD) in microglia [33]. A number of studies also
hypothesize its involvement in cancer progression.
SIRT3 mainly inhibits mitochondrial ROS production
but also deacetylates and activates many mitochondrial
proteins, regulating proliferation, differentiation, and
survival [34, 35]. Recent data suggest that SIRT3 acts
as a tumor suppressor by inhibiting glycolysis metabol-
ism after the deacetylation and activation of pyruvate
dehydrogenase; thus, also the role of SIRT3 in cancer is
debatable. Much less is known about the remaining
SIRTs. Unlike other family members, SIRT4 lacks NAD
+-dependent deacetylase activity but exerts ADP-
Table 2 Most relevant sirtuin inhibitors
Compound Structure Enzyme activity Biological Effects Reference(s)
1,
splitomicin
O
O ySir2 IC50 = 60 μMSIRT1: no inhibition @500 μM
Minimal inhibitory concentration (MIC) in yeast of 0.49 μM. [37]
2,
HR-73
O
O
Br
SIRT1 IC50 = < 5 μM Decreased HIV transcription through viral Tat protein
acetylation.
[38]
3, 4
O
O
R
H3C
3 R = Br
4 R = CH3
3 SIRT2 IC50 = 1.5 μM
4 SIRT2 IC50 = 1.5 μM (racemate)
SIRT2 IC50 = 1.0 μM (R enantiomer)
Weak antiproliferative effects and increased α-tubulin
acetylation in MCF-7 breast cancer cells.
[39]
5,
EX-527, selisistat
N
H
Cl
O
NH2
SIRT1 IC50 = 0.098 μM
SIRT2 IC50 = 19.6 μM
SIRT3 IC50 = 48.7 μM
Induction of p53 acetylation in different cell lines.
Modulation of the acetylation status of the mutant
huntingtin via SIRT1 inhbition shown to restore
transcriptional dysregulation in models of Huntington’s
disease (HD) treatment.
In a first Phase II clinical trial found to be safe and well
tolerated in early stage HD patients at plasma levels
within the therapeutic concentration range in preclinical
HD models.
[40–44]
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Table 2 Most relevant sirtuin inhibitors (Continued)
6,
cambinol
N
H
NH
O
HO
S
SIRT1 IC50 = 56 μM
SIRT2 IC50 = 59 μM
SIRT3: no inhibition @300 μM
SIRT5: 42% inhibition @300 μM
Induces apoptosis in BCL6-expressing Burkitt lymphoma cells.
Reduces tumor growth of Burkitt lymphoma in a mouse
xenograft model.
Reduces neuroblastoma formation in N-Myc transgenic mice.
[45–50]
7,
AGK2 Cl
Cl
O
CN
O
NH
N
SIRT1 IC50 > 50 μM
SIRT2 IC50 = 3.5 μM
SIRT3 IC50 > 50 μM
Protective against Parkinson’s disease (PD) in different PD
models.
Induces caspase-3-dependent apoptosis and necrosis of
C6 glioma cells.
[24, 51]
8, tenovin-1
9, tenovin-6
Tenovin-1:
IC50s not determined due to lack
of water solubility
Tenovin-6:
SIRT1 IC50 = 21 μM
SIRT2 IC50 = 10 μM
SIRT3 IC50 = 67 μM
Tenovin-6
Cytotoxic to the ARN8 melanoma cells.
Delayes the growth of xenograft tumors derived from
ARN8 cells.
Decelerates the disease progression of chronic myelogenous
leukemia in mice model.
Potent antitumor activity in various human gastric cancer
cells via death receptor 5 (DR5) upregulation.
[52–54]
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Table 2 Most relevant sirtuin inhibitors (Continued)
10,
sirtinol
OH
N
H
N
O CH3
ySir2 IC50 = 70 μM
SIRT1 IC50 = 131 μM
SIRT2 IC50 = 49 μM
Inhibits the viability of MCF-7, H1299, DU145, PC3 and
HeLa cells.
Enhances the chemosensitivity to camptothecin and
cisplatin in DU145, PC3 and HeLa cells.
Promotes a signifcant growth inhibition or apoptosis in
cells from adult T-cell leukemia-lymphoma (ATL) and
HTLV-1-related cell lines.
[55–59]
11,
salermide
OH
N
H
N
O
CH3
SIRT1 IC50 = 43 μM
SIRT2 IC50 = 25 μM
Induces apoptosis in various cancer lines (mainly MOLT4,
KG1A, SW480, and Raji) but not in normal cells (MRC5)
through inhibition of SIRT1 in a p53-independent manner.
Induces apoptosis in NSCLC cells through upregulation of
CDR5.
Exerts potent antiproliferative effects on MOLT4, MDA-MB-
231 and RKO cancer cells and in colorectal carcinoma
(CRC) and glioblastoma multiforme (GBM) cancer stem
cells (CSCs).
Exerts cell protection effects in a C. elegans model of
muscular dystrophy.
Induces apoptosis and death of schistosomula, separation
of adult worm pairs and reduction in egg laying,
through inhibition of the S. mansoni specific sirtuin
[60–64]
12,
MC2141
O
N
NO O
SIRT1 IC50 = 9.8 μM
SIRT2 IC50 = 12.3 μM
Induces apoptosis in U937 cells.
Exerts significant antiproliferative effects on Raji , DLD1,
HeLa, and CRC and GBM CSCs.
[65, 66]
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Table 2 Most relevant sirtuin inhibitors (Continued)
13,
inauhzin
S
N
S
O
N
N
N
HN
SIRT1 IC50 = 0.7- 2 μM
SIRT2: no inhibition @50 μM
SIRT3: no inhibition @50 μM
Activates and stabilizes p53 by inhibiting SIRT1 activity
with consequent p53 acetylation and prevention of
MDM2-mediated p53 ubiquitylation.
Inhibits cell proliferation and promotes senescence and
tumor-specific p53-dependent apoptosis without
genotoxicity in different cell lines (mainly H460, HCT116,
and A549 cells).
Represses the growth of xenograft tumors derived from
p53-harbouring H460 and HCT116 cells.
[67]
14
N
N
S O
NH2
N
HN
S
O
O SIRT1 IC50 = 4 nM SIRT2IC50 = 1 nM
SIRT3 IC50 = 7 nM
Not reported [68]
15,
SirReal2
S
N
N
H
S
O
N
N SIRT2 IC50 = 0.14-0.44 μMSIRT1 22% inhibition @100 μM
SIRT3 no inhibition @100 μM
SIRT4 no inhibition @200 μM
SIRT5 no inhibition @200 μM
SIRT6 19% inhibition @200 μM
Hyperacetylation of α-tubulin and of the microtubule
network in HeLa cells (@20 μM).
Significant depletion of the SIRT2 substrate BubR1
(spindle assembly checkpoint protein) in HeLa cells.
No alteration of cell cycle distribution in HeLa cells.
[69]
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Table 2 Most relevant sirtuin inhibitors (Continued)
16-20
Aryl
S
N
N
S
O
N
N
R3
R5
R1
R4
R2
16 Aryl= 7-chloronaphthalen-1-yl; R1= H; R2=
H; R3= CH3; R4= H; R5= CH3
17 Aryl= naphthalen-1-yl; R1= H; R2= (S)-CH3;
R3= CH3; R4= H; R5= CH3
18 Aryl= 7-bromonaphthalen-1-yl; R1= H; R2=
H; R3= CH3; R4= H; R5= CH3
19 Aryl= 2-methylnaphthalen-1-yl; R1= H; R2=
H; R3= CH3; R4= H; R5= CH3
20 Aryl= 7-chloronaphthalen-1-yl; R1= H; R2=
C2H5; R3= CH3; R4= H; R5= CH3
16 SIRT2 IC50 = 0.18 μM
SIRT1 29% inhibition @200 μM
17 SIRT2 IC50 = 0.26 μM
SIRT1 no inhibition @200 μM
18 SIRT2 IC50 = 0.21 μM
SIRT1 no inhibition @200 μM
19 SIRT2 IC50 = 0.31 μM
SIRT1 no inhibition @200 μM
20 SIRT2 IC50 = 0.32 μM
SIRT1 no inhibition @200 μM
Hyperacetylation of α-tubulin and of the microtubule
network in HeLa cells (16 @10 μM).
[70]
21
O
N
NH2
O
HN O
SIRT2 IC50 = 48.3 nM
SIRT1 IC50 = 12 μM
SIRT3 IC50 = 44.2 μM
Time-dependent and dose-dependent
hyperacetylation of α-tubulin in MCF-7 cells.
Modest cytotoxic effects (CC50 26-33μM) in human
cancer cell lines (MCF-7, K562 and DU145).
[71]
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Table 2 Most relevant sirtuin inhibitors (Continued)
22, 23
Cl
Br
O
O
22 R =
23 R =
N
O N
N
R
22 SIRT2 IC50 = 3.7 μM
23 SIRT2 IC50 = 12.2 μM
SIRT1/3 no inhibition @200 μM
for both compounds
Dose-dependent hyperacetylation of α-tubulin in MCF-7
cells.
Dose-dependent antiproliferative effects on MCF-7 and
A549 cancer cells.
[72, 73]
24,
AK-7 Br
H
N
S
N
O O
O
SIRT2 IC50 = 15.5 μM
SIRT1/3 no inhibition @50 μM
Neuroprotective reduction of total neuronal cholesterol
biosynthesis in a SIRT2 inhibition-dependent way.
Neuroprotective effects in different models of
Huntington’s disease and Parkinson’s disease.
[74–76]
25,
SDX-437
N
O
O
Br
OMe
OEt
SIRT3 IC50 = 700 nM
SIRT1 no inhibition @100 μM
Not reported. [77]
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Table 2 Most relevant sirtuin inhibitors (Continued)
26
O
N
H
O H
N
O
COOH
OH
SIRT6 IC50 = 89 μM
SIRT1 IC50 = 1578 μM
SIRT2 IC50 = 751 μM
Hyperacetylation of SIRT6 substrate H3K9 in pancreatic
adenocarcinoma BxPC-3 cells.
Glucose uptake increase, dose-dependent upregulation of
GLUT-1 expression and reduction of TNF-α secretion in
BxPC-3 cells.
[78]
27, 28
O
27 R1 =
28 R1 =
O
N
H
H
N
O
NH
R1
S
O
O
O
27 SIRT1 IC50 = 3.9 μM
28 SIRT1 IC50 = 2.7 μM SIRT2 IC50 = 23 μM
SIRT3 IC50 > 100 μM
Not reported. [84, 85]
29
O
O
N
H
H
N
O
HN
S
O
O
SIRT1 IC50 = 0.9 μM SIRT2 IC50 = 3 μM
SIRT3 IC50 = 8 μM
Antiproliferative effect in A549 lung
carcinoma and MCF-7 breast carcinoma
cell lines.
[86, 87]
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Table 2 Most relevant sirtuin inhibitors (Continued)
30
O
O
N
H
H
N
O
HN
S
NH
O
SIRT1 IC50 = 6 μM SIRT2 IC50 = 26 μM
SIRT3 IC50 = 29 μM
Antiproliferative effect in A549 lung
carcinoma and MCF-7 breast carcinoma
cell lines.
[86, 87]
31-33
Ac-Ala
N
H
O
HN R1
X
Ala-OH
31 X = O, R1 =
32 X = O, R1 =
33 X = S, R1 =
31 SIRT1 IC50 = 11 μM SIRT2 IC50 = 77 μM
32 SIRT1 IC50 = 12 μM SIRT2 IC50 = 30 μM
33 SIRT1 IC50 = 0.7 μM SIRT2 IC50 = 4 μM
Not reported. [88]
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Table 3 Most relevant sirtuin activators
Compound Structure Enzyme activity Biological Effects Reference(s)
34,
resveratrol
HO
OH
OH
SIRT1 EC1.5
a = 46.2 μM Improves mitochondrial functions and protects against fat
diet-induced obesity (DIO). In obese mice leads to
increased health-span and lifespan.
Promising effects and in clinical trials for the treatment of
some diseases of aging (metabolic disorders, type 2
diabetes, etc.).
[91–96,
106–109]
35-37
N
S N
HN
OCH3
OCH3
OCH3
O
R1
N
N
35, SRT1460 R1=
36, SRT1720 R1=
37, SRT2183 R1=
R2= HN
N
R2= HN
N
R2= N
HO
R2
35 SIRT1 EC1.5 = 2.9 μM
SIRT1 max act.b 447%
36 SIRT1 EC1.5 = 0.16 μM
SIRT1 max act. 781%
37 SIRT1 EC1.5 = 0.36 μM
SIRT1 max act. 296%
All SRT compounds, with different potencies, improve insulin
sensitivity in DIO and genetically obese mice (Lepob/ob), lower
plasma glucose and increase mitochondrial capacity.
In Zucker fa/fa rats, improve whole-body glucose
homeostasis, insulin sensitivity in adipose tissue, skeletal
muscle and liver, and mitochondrial bioenergetics in a
SIRT-1 dependent manner.
Very good activities in different age-related disease
conditions.
[95, 97–101]
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Table 3 Most relevant sirtuin activators (Continued)
38,
STAC-8
N
NHO
N S
O
N
N
F3C
SIRT1 EC1.5 = 1.2 μM
SIRT1 max act. 890%
Promising activities in different age-related disease
models: obesity and metabolic disorders, inflammatory
and autoimmune disorders, cardiovascular disease,
hepatic steatosis, neurodegeneration, and cancer.
[99–101]
39
N N
O
HN
O
OCH3
N
OCH3
NH
SIRT1 EC1.5 = 0.5 μM
SIRT1 max act. 220%
Not reported. [99–102]
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Table 3 Most relevant sirtuin activators (Continued)
40, 41
N
H
N
N
40 R= H
41 R=
HN
O
NN
R
NH
40 SIRT1 EC1.5 = 0.3 μM
SIRT1 max act. 253%
41 SIRT1 EC1.5 = 0.4 μM
SIRT1 max act. 820%
Not reported. [99–102]
42-44
N
S
HN
N
N
O
N
R
42 R= Piperazin-1-yl
43 R= Morpholin-4-yl
44 R= HN OH
OH
EC1.5 < 250 nM
SIRT1 max act. ≥300%
Not reported. [99–101,
103]
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Table 3 Most relevant sirtuin activators (Continued)
45,
STAC-5
N
N
H
N
NHO
N S
F3C
SIRT1 EC1.5 = 0.4 μM
SIRT1 max act. 1310%
Promising activities in different age-related disease models:
obesity and metabolic disorders, inflammatory and
autoimmune disorders, cardiovascular disease, hepatic
steatosis, neurodegeneration, and cancer.
[99–101,
104]
46
N
OO
R2
R1R1
46
Ar
Ar = aryl, heteroaryl
R1 = OEt, OH, NH2
R2 = benzyl, benzoyl, acyl, etc.
46a (MC2562) (Ar = Ph, R1 =
OEt, R2 = benzyl):
SIRT1 EC1.5 ≈ 1 μM
SIRT2 EC1.5 = 25 μM
SIRT3 EC1.5 ≈ 50 μM
Induce α-tubulin hypoacetylation in U937 cells and reduce
the number of senescent cells of 30-40% in human
mesenchymal stem cells.
Increase NO release in HaCat cells, and accelerate tissue
renewal in a mouse model of skin repair. In C2C12 myoblasts
improve mitochondrial density and functions through
activation of the SIRT1/AMPK axis. A water-soluble analog
displays antiproliferative effect and increased H4K16
deacetylation in a panel of human cancer cells at 8-35 μM
[111–113]
47,
honokiol HO OH
Increases SIRT3 levels by
nearly two-fold @5μM and
10μM in cardiomyocytes after
24h treatment.
In vitro directly binds to SIRT3
and increases the affinity of
SIRT3 for NAD+.
Blocks hypertrofic response of cardiomyocytes in vitro.
Protects mice from developing cardiac hypertrophy,
attenuates pre-established cardiac hypertrophy in mice,
reduces ROS production and prevents cardiomyocyte death
in a SIRT3-dependent manner.
[114]
aConcentration of compound required to increase enzyme activity by 50 %
bMaximum percentage of activation achieved at the highest tested dose
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duced by DNA damage including chemotherapy and γ-
irradiation and is capable of arresting the cell cycle by
inhibiting mitochondrial glutamine metabolism. SIRT4
inhibits proliferation, invasion, and migration in colo-
rectal cancer cells, and its low expression is correlated
with a worse prognosis [36]. SIRT5 is reported to inter-
act with carbamoyl phosphate synthetase 1 (CPS1), and
it is deacetylated by SIRT5. The role of SIRT5 in car-
cinogenesis remains unclear, but a recent study showed
its overexpression in non-small cell lung cancer tissues
as a marker of low survival [37]. SIRT6 was reported to
display actions controlling cellular homeostasis, DNA
repair, telomere maintenance, and metabolism, acting
as an epigenetic guardian for cellular differentiation
[38]. Recent studies have highlighted SIRT7 as a prom-
ising target for epigenetic cancer therapy. SIRT7 cata-
lyzes selective deacetylation of H3K18, an emerging
epigenetic biomarker of aggressive tumors, controlling
many tumor suppressor genes. High expression of
SIRT7 has in fact been associated with aggressive can-
cers and low survival, whereas its depletion leads to a
less aggressive phenotype [39]. A recent report de-
scribed the use of chlorpromazine to inhibit cell cycle
progression in rat glioma cells and induce autophagic
cell death. The authors demonstrate that an FDA-
approved drug used to treat schizophrenia and bipolar
disorder is able to increase p53 Lys382 acetylation
through a mechanism of SIRT1 inhibition [40].
SIRT inhibition—small molecules
Many SIRT modulators, used alone or in combination
with other epigenetic modulators or known drugs, have
been described as having beneficial effects against neuro-
degeneration and cancer [41]. Identified in 2001 from a
yeast-based screening for inhibitors of Sir2, splitomicin
(1, Table 2), despite being substantially inactive against
hSIRTs, has been the starting point for the development
of several SIRT1/2 inhibitors [42]. Among them, the
compound with a phenyl ring on 2-position and a brom-
ine on 8-position indicated as HR-73 (2, Table 2) is a
single-digit micromolar SIRT1i that inhibits HIV tran-
scription through affecting the Tat protein acetylation
[43]. In a series of splitomicin analogs carrying a phenyl
ring on 3-position and different substituents on 8-
position, compounds 3 and 4 (Table 2), respectively,
revealed to be low micromolar SIRT2i able to exert anti-
proliferative effects and cause α-tubulin hyperacetylation
in MCF-7 cells [44]. Discovered in 2005, EX-527 (selisi-
stat, 5, Table 2) was the first potent, selective (over
SIRT2/3), and cell-permeable SIRT1i [45, 46]. Despite
increasing p53 acetylation, EX-527 has no major effect
on viability and proliferation in various tumors [47]. EX-
527 is being developed for HD. A phase II clinical studyrecently demonstrated that EX-527 is safe and well toler-
ated in HD patients at plasma concentrations, providing
benefit in non-clinical HD models [48]. Recently, EX-
527 was also found to block the amplification of human
papillomavirus via a SIRT1 inhibition-dependent mech-
anism [49]. Identified in 2006, cambinol (6, Table 2) is a
moderate SIRT1/2i that induces hyperacetylation of p53,
α-tubulin, FOXO3a, and Ku70 in NCI-H460 and HeLa
cancer cells; promotes apoptosis in BCL-6-expressing
Burkitt lymphoma cells; and reduces tumor growth in a
xenograft model [50]. It is also endowed with anticancer
effects on hepatocellular carcinoma tumor models
in vitro and in vivo [51] and reduces neuroblastoma for-
mation in N-Myc transgenic mice [52]. These promising
results stimulated various optimization efforts, leading
to the identification of derivatives/analogs with increased
potency/selectivity for either SIRT1 or SIRT2 [53–55].
Discovered through a focused library screening, AGK2
(7, Table 2) is a single-digit micromolar SIRT2i selective
over SIRT1/3. Able to inhibit the deacetylation of α-
tubulin in HeLa cells, AGK2 rescues dopaminergic neu-
rons from α-synuclein toxicity and protects against PD
in different PD models [25]. Likely through SIRT2 inhib-
ition, AGK2 also induces caspase-3-dependent death in
glioma cells [56]. A cell-based screen designed to detect
p53 activators identified tenovin-1 (8, Table 2) and its
water-soluble analog tenovin-6 (9, Table 2) as SIRTi.
Tenovin-6 is a micromolar SIRT1-3i that increases the
level of p53K382ac; shows cytotoxic effects on melan-
oma cells, delaying the growth of ARN8-derived xeno-
graft tumors [57]; and induces apoptosis in gastric
cancer cells [58] and in chronic myeloid leukemia cells,
decelerating the disease progression in mice models
[59]. Discovered in 2001 by a high-throughput cell-
based screening, sirtinol (10, Table 2) is a micromolar
ySir2 and hSIRT1/2 inhibitor endowed with various anti-
cancer activities [60]. It induces senescence-like growth
arrest in human MCF-7 and H1299 cells [61]; inhibits
the growth of PC3, DU145, and HeLa cells, enhancing
their chemosensitivity to cisplatin and camptothecin
[62, 63]; and promotes significant growth inhibition or
apoptosis in cells from adult T cell leukemia-lymphoma
(ATL) [64]. Salermide (11, Table 2), which resulted
from the med-chem optimization of sirtinol, is a moderate
SIRT1/2i that induces cancer-specific pro-apoptotic ef-
fects on different tumor cells (mainly MOLT4, KG1A,
SW480, and Raji) through reactivation of pro-apoptotic
genes (CASP8, TNF, TNFRSF10B, and PUMA) previously
repressed by SIRT1-mediated H4K16ac deacetylation [65]
and through the upregulation of DR5 [66]. Salermide and
its analogs also show potent antiproliferative effects on
cancer stem cells [67] and exert cell protection effects on
a C. elegans model of muscular dystrophy [68]. In infec-
tious diseases (Schistosoma mansoni), salermide was the
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and death of schistosomula, in separation of adult worm
pairs and in reduction in egg laying, through inhibition of
the S. mansoni specific sirtuin [69]. Identified in 2010 as
result of cambinol manipulation, MC2141 (12, Table 2) is
the prototype of a series of benzodeazaoxaflavins active as
low micromolar SIRT1/2i. MC2141 displays significant
pro-apoptotic and antiproliferative properties in different
cancer cell lines, including cancer stem cells [70, 71].
Identified in 2012 in a virtual screening for inhibitors of
the p53-MDM2/MDMX interaction, inauhzin (13, Table 2)
is a (sub)micromolar SIRT1i selective over SIRT2/3 able
to exert antiproliferative and tumor-specific pro-apoptotic
effects on various cancer lines by activating and stabilizing
p53. Inauhzin represses the growth of xenograft tumors
derived from p53-harboring H460 and HCT116 cells [72].
The most potent SIRTi reported to date are thieno[3,2-
d]pyrimidine-6-carboxamides that resulted from a SAR
analysis of the hit compounds deriving from a DNA-
encoded small molecule library screen [73]. Although the
most potent compound in the series (14, Table 2) is active
in the single-digit nanomolar range against SIRT1–3 and
its binding mode has been elucidated by X-ray crystallog-
raphy, no biological activities are currently known for
these compounds. Very recently, SirReal2 (15, Table 2)
was reported as a submicromolar SIRT2i with >1000-fold
selectivity over SIRT1/3/4/5/6 [74]. Its potency and select-
ivity, as revealed by X-ray crystallography, are based on a
ligand-induced structural rearrangement of the SIRT2 ac-
tive site revealing a previously unexploited binding pocket.
The SIRT2 inhibition capability of SirReal2 has been con-
firmed in HeLa cells by the induction of α-tubulin hypera-
cetylation and the destabilization of the SIRT2 substrate
BubR1. A subsequent SAR investigation on the prototype
led to the development of some derivatives (16–20,
Table 2) with improved SIRT2i potency [75].
An elegant fragment-based approach inspired by the
structures of the SIRTi suramin and nicotinamide re-
cently identified a nanomolar SIRT2-selective (over
SIRT1/3) inhibitor (21, Table 2), which is able to induce
clear time-dependent and dose-dependent hyperacety-
lation of α-tubulin in MCF-7 cells and shows cytotoxic
effects on some cancer cell lines [76]. In recent years, a
series of chroman-4-one derivatives as low micromolar
SIRT2i selective over SIRT1/3 has been reported [77, 78].
Among them, compounds 22 and 23 (Table 2) are the
most attractive in terms of their overall pharmacological
profile as they display good dose-dependent α-tubulin
hyperacetylation and significant antiproliferative effects on
cancer cells (MCF-7 and A549). From the screening of a
panel of polyglutamine aggregate inhibitors, AK-7 (24,
Table 2) was identified in 2011 as a brain-permeable mi-
cromolar SIRT2 selective (over SIRT1/3) inhibitor able to
reduce neuronal cholesterol biosynthesis [79]. In addition,AK-7 displays other SIRT2 inhibition-dependent neuro-
protective effects on various models of HD [80] and PD
[81], supporting the development of SIRT2i as potential
therapeutics for these disorders. Very recently, by high-
throughput screening employing self-assembled mono-
layer desorption/ionization mass spectrometry, the first
submicromolar small molecule inhibitor of SIRT3,
SDX-437 (25, Table 2), was identified. SDX-437 is
>100-fold selective over SIRT1 and could be a useful
tool for studying SIRT3 biology and a promising lead
for future med-chem optimization campaigns [82]. By
a high-throughput molecular docking screen, com-
pound 26 (Table 2) was recently identified as the first
micromolar small molecule inhibitor of SIRT6 with
>eightfold selectivity over SIRT1/2 [83]. Although this
molecule needs optimization, it can be considered as a
promising lead for the functional annotation of SIRT6
and the development of potential SIRT6-based thera-
peutics due to its ability to induce hyperacetylation of
the SIRT6 substrate H3K9, to increase glucose uptake
through the upregulation of GLUT-1, and to reduce
TNF-α secretion (BxPC-3 cells).SIRT inhibition—peptides and pseudopeptides
The first peptidic SIRTi was developed by replacing the
Nε-acetyl-lysine with a thioacetylated residue and by
using the C-terminus of p53 protein (H2N-KKGQS
TSRH(ThAcK)LMFKTEG-COOH) as a substrate pep-
tide template [84]. Based on kinetic studies, this thioace-
tylated peptide was able to form an intermediate tighter
than the acetylated peptide [84–86], showing a strong
SIRT1 inhibition (IC50 ~ 2 μM), and was also active
against SIRT2/3 (IC50 ~ 2 and 67 μM, respectively) [87].
More thioacetylated peptide inhibitors were developed
from other SIRT substrates such as human α-tubulin
and acetyl-coenzyme A synthetase 2 (AceCS2) [87, 88].
The α-tubulin [85–93]-based H2N-MPSD(ThAcK)-
TIGG-COOH inhibited SIRT2 at a low micromolar
level (IC50 ~ 11 μM), whereas it was less potent against
SIRT1/3. The thioacetylated AceCS2 (633–652) peptide
showed low micromolar inhibition of SIRT1–3 (IC50 ~
0.9, 4, and 5 μM, respectively) [87]. Thioacetylated α-
tubulin and p53-based tri-, tetra-, and pentapeptides were
developed in 2009 [88]. Several peptides had submicromo-
lar IC50s for SIRT1, such as tripeptide K(ThAcK)L
(0.57 μM) and pentapeptide HK(ThAcK)LM (0.18 μM).
The most potent inhibitor for SIRT2 was the pentapeptide
HK(ThAcK)AM (IC50 ~ 3.8 μM). The first small pseudo-
peptidic SIRTi was reported in 2009 [89]. The most potent
compound, NCS-12k (27, Table 2), showed an IC50 of
3.9 μM for SIRT1. Further modifications produced the
cell-active Cbz-Lys(ThAc)-NH-Ph (28, Table 2) with an
IC50 of 2.7 μM for SIRT1, 23 μM for SIRT2, but
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thioacetylated pseudopeptide inhibitors developed to im-
prove potency, selectivity, and cell permeability, com-
pounds 29 and 30 (Table 2) were found to be micromolar
inhibitors of SIRT1-3 and showed antiproliferative effects
on cancer cells [91, 92]. Some pseudopeptidic inhibitors
were also tested against SIRT6, but potency was lower
[93]. Besides the thioacetyl group, several other lysine Nε-
modifications (such as propionyl, butyryl, α-hydroxyacetyl,
monofluoroacetyl, homocitrulline, homoarginine, difluor-
oacetyl, acetimidoyl, methanesulfonyl, selenoacetyl, and
trifluoroacetyl groups) have been reported [85, 86, 93–95].
Among the carbonyl-containing Nε-modifications studied
on the sequence Ac-AKA-OH, the most potent were Nε-
3,3-dimethylacryl (31, Table 2) and Nε-isovaleryl (32,
Table 2) with IC50s in the micromolar range against
SIRT1/2, while Nε-isothiovaleryl (33, Table 2) improved
potency giving SIRT1/2 IC50s in the (sub)micromolar
range [95].
SIRT activators
The natural polyphenol resveratrol (34, Table 3) was
the first SIRT1a described. Its administration extends
lifespan in yeast, Caenorhabditis elegans, Drosophila,
fishes, and bees [96–99]. Mice treated with resveratrol
display improved mitochondrial functions and protec-
tion against high-fat diet-induced obesity [100], while
in obese mice, treatment with resveratrol leads to in-
creased healthspan and lifespan [101]. Identified in
2007 by high-throughput screening as selective SIRT1a
more potent than resveratrol, SRT compounds (35–37,
Table 3) reproduce most of resveratrol beneficial effects
in vivo. In diet-induced and genetically obese (Lepob/ob)
mice, compounds 35–37 (Table 3) improve insulin sen-
sitivity, lower plasma glucose, and increase mitochon-
drial capacity. Moreover, in Zucker (fa/fa) rats, the
same compounds improve whole-body glucose homeo-
stasis and insulin sensitivity [95]. Due to their very
promising activities, some of the most potent SRTs are
currently in clinical trials for the treatment of different
age-related diseases [102–106]. The most potent scaf-
folds proposed as sirtuin-activating in terms of SIRT1
activation (EC1.5 values in the submicromolar range)
and the most effective in the treatment of age-related
conditions (obesity, metabolic and cardiovascular disor-
ders, inflammatory/autoimmune diseases, neurodegen-
eration, and cancer) are pyrido[3,2-b][1, 4]oxazocines
(38, Table 3) [104–106]; oxazolo[4,5-b]pyridines and
benzo[d]imidazoles (39–41, Table 3) [104–107]; thiazo-
lopyridines (42–44, Table 3) [104–106, 108]; and aza-
benzimidazoles (45, Table 3) [104–106, 109]. Over the
past years, it has been highly debated the effective
SIRT1 activation by resveratrol and SRT compounds,
because only the use in the enzyme assays ofaminomethylcoumarin (AMC)- or carboxytetramethylr-
hodamine (TAMRA)-labeled substrates allowed to see
activation, whereas in the presence of natural substrates
no activation was observed [110–112]. For this reason,
it was questioned if the action of resveratrol and SRT
compounds on SIRT1 is the result of a direct activation,
or if rather it arises from the indirect modulation of
other pathways, such as AMPK activation and/or PDE
inhibition [113]. Recently, direct SIRT1 activation has
been confirmed, and it has been shown that there are
subtle structural and positional requirements to detect
SIRT1 activation with some of its natural substrates
(e.g., FOXO3a and PGC-1α) [104, 114]. Moreover,
E230K or E230A SIRT1 mutation abolishes enzyme ac-
tivation as well as binding of SRT compounds, suggest-
ing an assisted allosteric activation mechanism in
which the activators bind and stabilize the enzyme-
substrate complex promoting the deacetylation reaction
[104]. Lastly, the crystal structure of a SRT compound
bound to an engineered minimally functional hSIRT1
has been reported, unambiguously confirming the dir-
ect allosteric activation of SIRT1 by small molecules
[115]. The 1,4-dihydropyridine (DHP) scaffold with
general formula 46 (Table 3) has been described as a
new chemotype for SIRT activation. Selected DHPs in-
duced hypoacetylation of α-tubulin in U937 cells, high
NO release in HaCat cells, and ameliorated skin repair
in a mouse model of wound healing. In myoblasts, they
improved mitochondrial density and functions through
activation of the SIRT1/AMPK axis. A water-soluble
analog displayed antiproliferative action and increased
H4K16ac deacetylation in a panel of cancer cells at 8–
35 μM [116–118]. Very recently, the cardiac anti-
hypertrophic effects of the natural compound honokiol
(47, Table 3) were reported to depend on the pharma-
cological activation (increased expression and activity)
of SIRT3 [119].Conclusions
A critical analysis of current knowledge and recent dis-
coveries clearly indicates that SIRT modulation is benefi-
cial against several diseases including cancer and
neurodegeneration. Chronic diseases, such as obesity
and diabetes, might also likely benefit from SIRT target-
ing, but further investigation is needed. The ubiquitous
expression of some SIRTs, together with the fact that
many studies primarily investigated SIRT1 only, and not
all the other family members, still leaves room for some
confusion. Currently, for example, activation or inhib-
ition of SIRTs (even the same SIRT) is described as
beneficial for pathologies such as neurodegeneration.
Despite the apparent contradiction, this is theoretic-
ally possible when taking into account the role of
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domain of the single enzyme. Furthermore, both the
chemistry and biomedical characterization of SIRTa
are at a much earlier stage of development than
SIRTi, thus suggesting that new alternatives may arise
in the near future. Finally, the potential selective
modulation of SIRT family members will represent a
promising area provided that new selective molecules
can be designed.
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